Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Center Seeks Panel’s Advice On Conveying Product Risks

This article was originally published in The Gray Sheet

Executive Summary

FDA says it tries to proactively communicate device risks to physicians and patients, but unique challenges in the industry sometimes hinder its efforts

You may also be interested in...



When Communicating Product Risks, FDA Should Involve Firms – AdvaMed

AdvaMed is urging FDA to "routinely" consult with manufacturers when developing and evaluating safety-related communications about devices, drugs and other regulated products

When Communicating Product Risks, FDA Should Involve Firms – AdvaMed

AdvaMed is urging FDA to "routinely" consult with manufacturers when developing and evaluating safety-related communications about devices, drugs and other regulated products

Race For FDA Commissioner Almost Over: Will It End With Sharfstein Or Califf?

The Obama transition team has concluded its search for a new FDA commissioner, stakeholders said late last week

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel